 CAMBRIDGE, Mass., Feb. 17, 2021 GLOBE NEWSWIRE -- Solid Biosciences Inc. Nasdaq: SLDB, a life sciences company focused on advancing meaningful therapies for Duchenne muscular dystrophy Duchenne, today announced that Joel Schneider, PhD, Chief Technology Officer, and Cathryn Clary, MD, MBA, Acting Chief Medical Officer, will participate at the following two upcoming investor conferences: 